Braids and conditioner may boost scalp cooling against chemo hair loss

NCT ID NCT05213936

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests whether special hairstyling methods — like braids, cornrows, or a conditioner-and-water mix — can help scalp cooling caps work better to prevent hair loss during chemotherapy. It focuses on people with curly or kinky hair (types 3 and 4), who have been underrepresented in past scalp cooling research. Participants are women with breast, lung, or gynecologic cancer starting taxane-based chemotherapy. The study also looks at long-term hair regrowth and genetic markers linked to scalp cooling success.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
scalp cooling device with hairstyling techniques (braids/cornrows/twists or conditioner/water emulsion)
What this could lead to
If successful, this could make scalp cooling more effective for people with curly or kinky hair, reducing chemotherapy-related hair loss in a group often underrepresented in prior studies.
What could go wrong
This is a small, early-stage study with only 41 participants, so results may not apply to everyone. The techniques may not work for all hair types or chemotherapy regimens.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 41 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2022

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age \>= 18 years 2. Female 3. Hair type 3 (curly) or type 4 (kinky) 4. Diagnosis of breast cancer or non-small cell lung cancer (NSCLC) or gynecologic cancer stage I-IV 5. Patient will be starting \>= 4 cycles of taxane-based chemotherapy treatment for curative intent after enrollment a. Concurrent HER, cisplatin, cyclophosphamide therapies and doxorubicin therapies allowed 6. Eastern Cooperative Oncology Group (ECOG) 0-2: fully active, restrictive in physically strenuous activity, ambulatory and capable of self-care Exclusion Criteria: 1. Hair type other than 3 or 4 2. Male 3. Use of hair weave or extensions without plans to remove 4. Concurrent malignancy including hematologic malignancies (i.e. leukemia or lymphoma) 5. Alopecia Common Terminology Criteria for Adverse Events \> grade 1 at baseline 6. Past chemotherapy administration if past treatment was \<= 10 years ago 7. History of migraines or cluster headaches, anorexia, severe anemia, uncontrolled diabetes, hepatitis, thyroid dysfunction, cold urticaria, cold agglutinin disease, scalp metastases 8. Planned bone marrow ablation chemotherapy or skull irradiation 9. Pregnant patient

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alopecia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Montefiore Medical Center

    RECRUITING

    The Bronx, New York, 10461, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.